Global Ganja Report

As legal cannabis finally becomes a reality in Canada, a policy patchwork across the country's provinces and ongoing political tussles have left many confused as to what the new system will actually look like. We break down some of the frequently asked questions. 

A growing number among Canada's First Nations are looking to legal cannabis as a path to economic empowerment. Others are deeply skeptical, recalling the bitter history of substance abuse among Canada's indigenous communities. Yet all seem united in demanding sovereign control on the cannabis question within their own reserves.

A legal medical marijuana export industry is coming to Jamaica, which has just dispatched its first shipment of cannabis oil to Canada. Long famous for its contraband product, the island nation now has a Cannabis Licensing Authority to oversee legal cultivation.

After years of upholding employee firings for use of cannabis even under state medical marijuana programs, the courts are finally starting to turn around on the question.

One of the ways state medical marijuana programs have failed to fully extend protection to medicinal users is in failure to defend against employment discrimination. This is now beginning to change, thanks to a few recent court decisions in favor of patients and employees.

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.

Among several cannabis-related bills signed into law by California's Gov. Jerry Brown was one creating an "equity" program for the state's legalized industry, aimed at justice and inclusion for those communities hardest hit by marijuana prohibition. Another measure will erase past convictions for possession of cannabis in quantities that are now legal.

With the DEA's rescheduling of Epidiolex, shares in the British manufacturer of the drug are soaring. But CBD—the actual cannabinoid that the product is based on—is to remain in the restrictive Scheudle 1.

As the UN General Assembly met in New York, President Trump issued a "Global Call" to renew the war on drugs—to the dismay of activists and dissenting nations. But the UN itself has a contradictory cannabis policy—with some agencies recognizing its efficacy as medicine and others backing the prohibitionist doctrine of the Single Convention treaty.